IMR Press / FBL / Volume 8 / Issue 4 / DOI: 10.2741/1008

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Proteomics in primary brain tumors
Show Less
1 Department of Pathology, Erasmus Medical Center Rotterdam, The Netherlands
2 Department of Neurology, Erasmus Medical Center Rotterdam, The Netherlands

Academic Editor: Van Meir

Front. Biosci. (Landmark Ed) 2003, 8(4), 451–463;
Published: 1 January 2003
(This article belongs to the Special Issue Encyclopedia of neuro-oncology)

Genomic damage present in tumors may lead to abnormal or altered expression of proteins. Some of the findings of genetic explorations of brain tumors have had their impact on making the diagnosis or are important with respect to therapeutic decisions. The identification of individual proteins or clusters of proteins expressed in neoplastic tissues potentially may have an even more important relevance for making the diagnosis, prognosis and treatment outcome. Diverse posttranslational modifications of proteins may be linked to neoplastic lineage or stage. For the rapidly developing fields of proteomics and its integration with genomics and transcriptomics (by now called operomics) the application of bioinformatics is crucial. This review addresses the nascent field of proteomics and its diagnostic potential in the feld of primary brain tumors. Various technical approaches to separate and identify proteins are described, including the most recent developments in the analytical proteomic technology.

Back to top